P21.13 Durvalumab in Locally-Advanced NSCLC in LATAM: Real World Data from Patients Included in the Early Access Program

Abstract

The event-free survival (EFS) and overall survival (OS) were estimated by the KaplaneMeier method and compared between patients at different disease characteristics using the log-rank test. Results: There are total 3151 patients across 19 countries, including 200 patients in Taiwan subgroup. The EFS and OS of total population were 10.3 (interquartile range, 8.8 to 11.8) months and 24.8 (interquartile range, 21.3 to 27.4) months, respectively. The patients with stage IIIA and stage IIIB NSCLC have similar median EFS (11.4 vs. 9.2 months, respectively; P ¼ 0.143) and median OS (29.5 vs. 24.1 months, respectively; P ¼ 0.085). In contrast, patients with resectable disease have better median EFS (13.4 vs. 8.6 months, respectively; P ¼ 0.014) and OS (33.9 vs. 20.5 months, respectively; P < 0.001) than patients with unresectable disease. Moreover, in either resectable subgroup or unresectable subgroup, both the EFS and OS were also similar between patients with stage IIIA and IIIB NSCLC. These data indicate that the resectability is a more important prognostic factor than stage among patients with stage III NSCLC. Among 55 patients with resectable disease, 53 underwent the surgery and 2 received chemo-radiotherapy (CRT)-based therapy. The median EFS was significantly longer in patients undergoing the surgery compared to those receiving CRT-based therapy (14.7 vs. 7.5 months, respectively; P ¼ 0.028); however, the median OS was not significantly different between the two cohorts (34.9 vs. 25.5 months, respectively; P ¼ 0.339). Among 116 patients with unresectable disease, 38 received curative-intent CRT-based therapy and 78 received palliative therapy. Both median EFS and OS were comparable between patients receiving different treatment approaches. Conclusion: In the Taiwanese subgroup of KINDLE study, the resectability is the major prognostic factor in patients with stage III NSCLC. Although the surgery seemed to result in better EFS in patients with resectable disease, the OS was similar among patients receiving different treatment approaches. Further subgroup analysis is warranted to explore the predictive value of other baseline characteristics (e.g., TNM stage, EGFR status, subsequent therapy).